IntelliCyt® Biologics Discovery program provides solutions for antibody screening
The HTFC Screening System and our “mix-and-measure” intact cell assay for primary screening simultaneously assesses antigen binding and cross-reactivity with higher throughput, greater sensitivity and dynamic range.
- measures cells in suspension, so epitopes can be measured in their native state
- reduces workflow steps and increases productivity
- reads a 384-well plate in under 15 minutes.
IntelliCyt customers report up to a 24X increase in throughput, dramatically increasing their opportunity for discovering antibodies to treat cancer, diabetes, cardiovascular disease, autoimmune diseases or AIDS. More Information»
Webinar Broadcast May 10, 2012
Re-tooling in Vitro Toxicology for the Changing Landscape of Drug Discovery
Joseph Zock discusses alternatives to animal testing, more relevant cell models, Hiigh Capacity Flow methods for multifaceted pathway assessment.
Kim Luu, Ph.D. previews her JBS publication: Profiling of Toxicity and Identification of Distinct Apoptosis Profiles Using a 384-Well High-Throughput Flow Cytometry Screening Platform View webinar»